{
    "nctId": "NCT00432562",
    "briefTitle": "A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.",
    "officialTitle": "A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion (ANX-530) in Patients With Advanced Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Non-small Cell Lung Cancer, Non-Hodgkins Lymphoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 31,
    "primaryOutcomeMeasure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \\> 18 years.\n* Advanced cancer potentially sensitive to vinorelbine:\n* Breast cancer.\n* Stage 3 or 4 non-small cell lung cancer.\n* Non-Hodgkins lymphoma.\n* Cancer of other histologic type, sensitive to vinca alkaloids.\n* Rare tumor type with no standard treatment, for which single agent vinorelbine is appropriate therapy.\n* Failure of standard treatment(s) of the tumor.\n* Life expectancy of at least three months.\n* ECOG performance level 0-2 or Karnofsky score 100-70.\n* Hematological and serum chemistry results with defined ranges.\n* Willingness and ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or lactation. In a woman of childbearing potential, a positive pregnancy test result, no pregnancy test result, or no use of reliable contraception, at baseline. A postmenopausal woman will be considered to be of childbearing potential until there has been amenorrhea for at least 12 consecutive months.\n* Previous treatment with vinorelbine or mitomycin.\n* Any history suggesting or demonstrating resistance to, lack of response to, or intolerance of any prior vinca alkaloid treatment.\n* Active infection.\n* Prior anticancer therapy completed within four weeks prior to the first day of study treatment.\n* Failure to have recovered from any toxicity of previous cancer treatment (patients with alopecia will not be excluded).\n* Participation in another experimental drug study within four weeks prior to the first day of study treatment.\n* Requirement for any concomitant chemotherapeutic agent other than the study medication.\n* Any investigator judgment that the individual would not be an appropriate study subject.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}